

# Hydrosoluble pyrenyl-dendrimers and arene ruthenium metallacages: Synergic enhancement of cytotoxicity


Anaïs Pitto-Barry,<sup>1</sup> Nicolas P. E. Barry,<sup>1</sup> Olivier Zava,<sup>2</sup> Paul J. Dyson,<sup>2</sup> Robert Deschenaux<sup>1</sup> and Bruno Therrien<sup>1</sup>

<sup>1</sup>Institut de Chimie, Université de Neuchâtel, Avenue de Bellevaux 51, 2000 Neuchâtel

<sup>2</sup>Institut des Sciences et Ingénierie Chimique, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne

## Introduction



Water-soluble dendrimers have been shown to improve drug solubility, increase drug circulation time and prolong drug residence in tumors, thus reducing toxicity.<sup>1</sup> Biodegradability is an important criteria in order to avoid cellular accumulation leading to lysosomal storage disease in patients.<sup>2</sup> Different generations of biodegradable water-soluble dendrimers were synthesised<sup>3</sup> and functionalised by a pyrenyl unit. This unit was then encapsulated into the hydrophobic cavity of hexanuclear arene ruthenium metallacages  $[Ru_6(p\text{-cymene})_6(OO\text{NOO})_3(\text{tpt})_2]^{6+}$  ( $\text{OO}\text{NOO}$  = 5,8-dioxyo-1,4-naphthoquinonato (dong) **[1]**<sup>6+</sup>, 6,11-dioxyo-5,12-naphtocenedionato (dotq) **[2]**<sup>6+</sup>; tpt = 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine).<sup>4</sup> The physical and chemical behavior as well as the biological activity of the host-guest systems are presented.<sup>5</sup>



Hexaruthenium metallacages


## Biological studies

Compound	A2780 ( $\text{IC}_{50}$ [ $\mu\text{M}$ ])	A2780cisR ( $\text{IC}_{50}$ [ $\mu\text{M}$ ])
pyr <sub>G1</sub>	n.d.	n.d.
pyr <sub>G2</sub>	n.d.	n.d.
pyr <sub>G3</sub>	n.d.	n.d.
pyr <sub>G1-OH</sub>	n.d.	n.d.
pyr <sub>G2-OH</sub>	5.9±0.6	7.4±0.8
pyr <sub>G3-OH</sub>	8.7±0.9	8.7±1.0
[1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	3.1±1.0	4.6±0.5
[2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	4.1±0.07	6.5±1.0
[pyr <sub>G1</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	1.2±0.1	0.9±0.08
[pyr <sub>G2</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	<b>0.3±0.02</b>	<b>0.2±0.02</b>
[pyr <sub>G3</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	0.7±0.3	0.8±0.2
[pyr <sub>G1-OH</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	1.4±0.1	0.9±0.08
[pyr <sub>G2-OH</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	2.0±0.5	1.3±0.4
[pyr <sub>G3-OH</sub> ⊂1][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	0.7±0.1	0.8±0.1
[pyr <sub>G1</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	2.1±0.4	1.6±0.2
[pyr <sub>G2</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	1.9±0.4	0.9±0.3
[pyr <sub>G3</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	<b>1.1±0.3</b>	<b>1.5±0.4</b>
[pyr <sub>G1-OH</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	0.8±0.3	2.2±0.8
[pyr <sub>G2-OH</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	4.1±0.6	1.9±0.3
[pyr <sub>G3-OH</sub> ⊂2][CF <sub>3</sub> SO <sub>3</sub> ] <sub>6</sub>	1.5±0.03	1.5±0.4
cisplatin	1.6±0.6	8.6±0.6



Synthesis of the pyrenyl bis-MPA dendrimers

## Encapsulation of guest in the metallaprism $[1]^{6+}$




## Conclusion

The combined host-guest systems are significantly more active than either the host or the guest alone. The enhanced cytotoxicity of the  $[\text{guest} \subset \text{cage}]^{6+}$  systems compared to the guest or host alone implies that intact  $[\text{guest} \subset \text{cage}]^{6+}$  systems are entering the cells together, and are responsible for the overall cytotoxicity observed.

The entrapment of water-soluble dendrimer guests within metalla-prism hosts leads to apparent enhancements in cytotoxicity. The host-guest system is also quite stable in biological media. These features, combined with their potential to preferentially accumulate in tumors, make them interesting candidates for further *in vivo* study and development.

- i. 2,2-dimethoxypropane, APTS, acetone, 2h, rt.
- ii. KOH, DMF, benzyl bromide, 12h, 100°C.
- iii. DCC, DPTS, dry CH<sub>2</sub>Cl<sub>2</sub>, 1h, 0°C then 19h, rt.
- iv. Dowex H<sup>+</sup>, MeOH, 3h, rt.
- v. H<sub>2</sub>, Pd/C, CH<sub>2</sub>Cl<sub>2</sub>/EtOH, 16h, rt.



1. M. E. Fox, F. C. Szoka, J. M. J. Fréchet, *Acc. Chem. Res.* **2009**, *42*, 1141. 2. M. A. Mintzer, M. W. Grinstaff, *Chem. Soc. Rev.* **2011**, *40*, 173. 3. a) H. Ihre, J. M. J. Fréchet, I. Gitsov, A. Hult, *Macromolecules* **1998**, *31*, 4061; b) A. Würsch, M. Möller, T. Gläuser, L. S. Lim, S. B. Voytek, J. L. Hedrick, C. W. Frank, J. G. Hilborn, *Macromolecules* **2001**, *34*, 6601; c) M. Malkoch, K. Hallman, S. Lutsenko, A. Hult, E. Mälmström, C. Moberg, *J. Org. Chem.* **2002**, *67*, 8197. 4: a) N. P. E. Barry, B. Therrien, *Eur. J. Inorg. Chem.* **2009**, 4695; b) J. Freudenreich, N. P. E. Barry, G. Süss-Fink, B. Therrien, *Eur. J. Inorg. Chem.* **2010**, 2400; c) F. Schmitt, J. Freudenreich, N. P. E. Barry, L. Juillerat-Jeanneret, G. Süss-Fink, T. Therrien, *J. Am. Chem. Soc.* **2012**, *134*, 754. 5: A. Pitto-Barry, O. Zava, P. J. Dyson, R. Deschenaux, B. Therrien, *Inorg. Chem.*, **2012**, *51*, 7119.